Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali Том 1 № 3 (2020)
SELECTION OF THE OPTIMAL DRUG FOR EMPIRICAL ANTIBACTERIAL THERAPY FOR TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
Даминова Лола Тургунпулатовна, Сиддиков Олим Абдуллаевич
Аннотация
Today pneumonia remains one of the most pressing diseases of humanity and ranks 4th in terms of mortality. The incidence of pneumonia depends on age, gender and comorbidities. The most common form of pneumonia is hospital-acquired pneumonia, and bacteria are one of the main causes of this pneumonia. For this reason, antibacterial drugs play an important role in the treatment of pneumonia. One of the main problems in carrying out antibiotic therapy is the choice of an antibacterial drug for empirical therapy during the period of increasing resistance of microbes to antibiotics. The results of scientific research, metanalysis, pharmacoepidemiological studies, as well as protocols and guidelines developed on their basis, will help to solve this problem.
внебольничная пневмония, антимикробные препараты, антибактериальная терапия, антибиотикорезистентность, β-лактамы, макролиды, цефалоспорины, фторхинолоныcommunity-acquired pneumonia, antimicrobial drugs, antibacterial therapy, antibiotic resistance, β-lactams, macrolides, cephalosporins, fluoroquinolonesshifoxonadan tashqari pnevmoniya, antimikrob preparatlar, antibacterial terapiya, antibiotikorezistentlik, β-laktamlar, makrolidlar, sefalosporinlar, ftorxinolonlar
Источник метаданных: OAI-PMH архив журнала · Sindex не хранит полный текст, а даёт ссылку на источник.